BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin A, Zhang H, Hu X, Chen X, Wu G, Luo P, Zhang J. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Pharmacol Res. 2020;159:105028. [PMID: 32569820 DOI: 10.1016/j.phrs.2020.105028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Wang C, Li S, Zhou H, Feng Y. Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma. Front Genet 2022;13:975419. [DOI: 10.3389/fgene.2022.975419] [Reference Citation Analysis]
2 Shi C, Qin K, Lin A, Jiang A, Cheng Q, Liu Z, Zhang J, Luo P. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res 2022;41:268. [DOI: 10.1186/s13046-022-02469-0] [Reference Citation Analysis]
3 Yu L, Gong C. Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes. Front Genet 2022;13:917118. [DOI: 10.3389/fgene.2022.917118] [Reference Citation Analysis]
4 Principe DR. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. Sci Rep 2022;12:11490. [PMID: 35798829 DOI: 10.1038/s41598-022-15714-5] [Reference Citation Analysis]
5 Feng W, Lin A, Sun L, Wei T, Ying H, Zhang J, Luo P, Zhu W. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. Cancer Cell Int 2022;22:186. [PMID: 35562800 DOI: 10.1186/s12935-022-02604-z] [Reference Citation Analysis]
6 Lin A, Qi C, Wei T, Li M, Cheng Q, Liu Z, Luo P, Zhang J. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Brief Bioinform 2022:bbac129. [PMID: 35395670 DOI: 10.1093/bib/bbac129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Yu J, Yang K, Zheng J, Sun X, Zhao W. Establishment of a novel prognostic signature based on an identified expression profile of integrin superfamily to predict overall survival of patients with colorectal adenocarcinoma. Gene 2022;808:145990. [PMID: 34624456 DOI: 10.1016/j.gene.2021.145990] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 李 晶. Association of NOTCH3 Mutation with the Prognosis of Colorectal Cancer Patients Treated with Immune Checkpoint Inhibitors. ACM 2022;12:6677-6685. [DOI: 10.12677/acm.2022.127963] [Reference Citation Analysis]
9 Pottoo FH, Iqubal A, Iqubal MK, Salahuddin M, Rahman JU, AlHajri N, Shehadeh M. miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy. Cancers (Basel) 2021;13:6145. [PMID: 34885253 DOI: 10.3390/cancers13236145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:759565. [PMID: 34777372 DOI: 10.3389/fimmu.2021.759565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
11 Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:751407. [PMID: 34659255 DOI: 10.3389/fimmu.2021.751407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Prayugo FB, Kao TJ, Anuraga G, Ta HDK, Chuang JY, Lin LC, Wu YF, Wang CY, Lee KH. Expression Profiles and Prognostic Value of FABPs in Colorectal Adenocarcinomas. Biomedicines 2021;9:1460. [PMID: 34680577 DOI: 10.3390/biomedicines9101460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lin A, Zhang H, Meng H, Deng Z, Gu T, Luo P, Zhang J. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol 2021;12:667875. [PMID: 34603277 DOI: 10.3389/fimmu.2021.667875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Zhang Y, Li X, Zhou R, Lin A, Cao M, Lyu Q, Luo P, Zhang J. Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma. Front Pharmacol 2021;12:723066. [PMID: 34512351 DOI: 10.3389/fphar.2021.723066] [Reference Citation Analysis]
15 Wang Y, Li X, Peng S, Hu H, Wang Y, Shao M, Feng G, Liu Y, Bai Y. Single-Cell Analysis Reveals Spatial Heterogeneity of Immune Cells in Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:638374. [PMID: 34513820 DOI: 10.3389/fcell.2021.638374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lin A, Wei T, Liang J, Qi C, Li M, Luo P, Zhang J. CAMOIP: A Web Server for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer.. [DOI: 10.1101/2021.09.10.459722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lyu Q, Lin A, Cao M, Xu A, Luo P, Zhang J. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. Cancer Control 2020;27:1073274820976665. [PMID: 33356494 DOI: 10.1177/1073274820976665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
18 Zhao L, Wang Q, Zhao SD, Zhou J, Jiang KW, Ye YJ, Wang S, Shen ZL. Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature. World J Clin Cases 2021; 9(24): 7099-7109 [PMID: 34540965 DOI: 10.12998/wjcc.v9.i24.7099] [Reference Citation Analysis]
19 Zhou X, Liu Y, Xiang J, Wang Y, Wang Q, Xia J, Chen Y, Bai Y. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy. Front Immunol 2021;12:665002. [PMID: 34367132 DOI: 10.3389/fimmu.2021.665002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
21 Zhao H, Danli S, Qian Z, Ye S, Chen J, Tang Z. Identifying GNG4 might play an important role in colorectal cancer TMB. Cancer Biomark 2021. [PMID: 34275892 DOI: 10.3233/CBM-203009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Wang Y, Chen H, Jiao X, Wu L, Yang Y, Zhang J, Wu L, Liu C, Zhuo N, Li S, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li J, Li Y, Lu Z, Zhang H, Shen L. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. Cancer Immunol Immunother 2021. [PMID: 34028566 DOI: 10.1007/s00262-021-02966-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jiao X, Wei X, Li S, Liu C, Chen H, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Wang Y, Wang Y, Zhuo N, Zhang H, Lu Z, Shen L. A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. NPJ Precis Oncol 2021;5:36. [PMID: 33947957 DOI: 10.1038/s41698-021-00172-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
24 Zhang Y, Lin A, Li Y, Ding W, Meng H, Luo P, Zhang J. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Front Cell Dev Biol 2020;8:608969. [PMID: 33363171 DOI: 10.3389/fcell.2020.608969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
25 Fan J, Shen X, Wang Y, Zhou HL, Liu G, Li YL, Xu ZX. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomed Pharmacother 2020;130:110621. [PMID: 34321165 DOI: 10.1016/j.biopha.2020.110621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Lin A, Zhang J, Luo P. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol 2020;11:2039. [PMID: 32903444 DOI: 10.3389/fimmu.2020.02039] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 41.5] [Reference Citation Analysis]
27 Li M, Wang H, Li W, Peng Y, Xu F, Shang J, Dong S, Bu L, Wang H, Wei W, Hu Q, Liu L, Zhao Q. Identification and validation of an immune prognostic signature in colorectal cancer. Int Immunopharmacol 2020;88:106868. [PMID: 32771948 DOI: 10.1016/j.intimp.2020.106868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]